Drug maker Merck & Co., Inc. (MRK) on Monday received some continued bullish support from analysts at UBS.
The firm maintained its “Buy” rating and $42 price target on UBS, which suggests an 8% upside to the stock’s Friday closing price of $38.94.
A UBS analyst noted he is not concerned right now about potential generic competition for the company’s Nasonex drug. On Friday, a New Jersey judge ruled that generic competitor Apotex does not infringe on Merck’s patent for mometasone furoate monohydrate.
Merck shares were mostly flat in late morning trading Monday.
The Bottom Line
Shares of Merck (MRK) have a 4.31% dividend yield, based on Friday’s closing stock price of $38.94. The stock has technical support in the $36 price area. If the shares can firm up, we see overhead resistance around the $39-$40 price levels.
Merck & Co., Inc. (MRK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here